Shire plc Shire Plc : Notice Of Results

TIDMSHP 
 
 
   Shire to announce second quarter 2018 results 
 
   Dublin, Ireland - July 23, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), 
will announce second quarter 2018 earnings on Tuesday July 31, 2018. 
 
 
 
 
Results press release will be issued at:  12:00 BST / 07:00 EDT 
Investor conference call time:            14:00 BST / 09:00 EDT 
 
   Live conference call for investors: 
 
   Flemming Ornskov, MD, M.P.H., Chief Executive Officer and Thomas 
Dittrich, Chief Financial Officer will host the investor and analyst 
conference call at 9:00 am EDT / 14:00 BST. 
 
   The details of the conference call are as follows: 
 
 
 
 
UK dial in:    0800 358 9473 or +44 333 300 0804 
US dial in:    1 855 857 0686 or 1 631 913 1422 
International  Click here: 
Access         http://events.arkadin.com/ev/docs/NE_W2_TF_Events_International_A 
Numbers:       ccess_List.pdf 
Password/Conf  45131838 # 
ID: 
Live Webcast:  Click here 
               http://investors.shire.com/presentations-and-reports/quarterly-re 
               sults-and-presentations 
 
   Replay: 
 
   A replay of the presentation will be made available, subject to approval 
by the UK Takeover Panel, for two weeks by phone and for three months by 
webcast.  Replay information made available will be contained on the 
Investor Relations section of Shire's website at 
http://investors.shire.com/. 
 
   For further information please contact: 
 
 
 
 
Investor Relations 
Christoph Brackmann   christoph.brackmann@shire.com   +41 41 288 4129 
Sun Kim               sun.kim@shire.com               +1 617 588 8175 
Scott Burrows         scott.burrows@shire.com         +41 41 288 4195 
 
Media 
Katie Joyce           kjoyce@shire.com                +1 781 482 2779 
 
 
   NOTES TO EDITORS 
 
   About Shire 
 
   Shire is the global biotechnology leader serving patients with rare 
diseases and specialized conditions. We seek to push boundaries through 
discovering and delivering new possibilities for patient communities who 
often have few or no other champions. Relentlessly on the edge of what's 
next, we are serial innovators with a diverse pipeline offering fresh 
thinking and new hope. Serving patients and partnering with healthcare 
communities in over 100 countries, we strive to be part of the entire 
patient journey to enable earlier diagnosis, raise standards of care, 
accelerate access to treatment, and support patients. Our diverse 
portfolio of therapeutic areas includes Immunology, Hematology, Genetic 
Diseases, Neuroscience, Internal Medicine, Ophthalmics, and Oncology. 
 
   Championing patients is our call to action - it brings the opportunity - 
and responsibility - to change people's lives. 
 
   www.shire.com 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Shire plc via Globenewswire

(END) Dow Jones Newswires

July 23, 2018 02:15 ET (06:15 GMT)

Shire Plc ADS, Each Representing Three Ordinary Shares (NASDAQ:SHPG)
Historical Stock Chart
From Mar 2024 to Apr 2024